India’s first CAR T-Cell therapy shows durable results
In a major milestone in Indian oncology care, Immuneel Therapeutics’ Made-In-India CAR T-cell therapy has delivered the country’s…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
CAR-T Therapy
Even drug-resistant cancer targets can be tackled with the right design strategy
Your work leverages AI and machine learning to optimise CAR-T cell therapy. How does this approach fundamentally differ from…
Evolution and commercialisation of cell and gene therapies
Satyen Sanghavi, Founder & CSO, Regrow Biosciences traces the evolution of cell and gene therapies, highlighting global…
CAR T cell therapies to promote drug-free remission in lupus care
BMS’s CC-97540 and Cabaletta Bio’s CABA-201 highlight CAR T’s potential to achieve lasting drug-free remission, marking a…
AstraZeneca to acquire Gracell Biotechnologies
Deal includes clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and…
US FDA approves Gilead cell therapy for earlier lymphoma
The one-time treatment was initially approved in 2017 for patients with large B-cell lymphoma who did not respond to at least two…
US FDA approves cancer therapy by Johnson & Johnson and Legend Biotech
The treatment, Carvykti/Cilta-cel, belongs to a class of drugs known as CAR-T therapies, or chimeric antigen receptor T-cell…